In an Eastern population, Guo et al. 16 evaluated 353 stage I-IV Chinese CRC patients, and the KRAS mutation rates in exons 2, 3, and 4 were 42.2% (149/353), 2.3% (8/353), and 8.2% (29/353), respectively. Here, KRAS is linked to colorectal carcinoma.